73.67
1.43 (1.98%)
| Penutupan Terdahulu | 72.24 |
| Buka | 72.50 |
| Jumlah Dagangan | 319,549 |
| Purata Dagangan (3B) | 379,860 |
| Modal Pasaran | 1,692,225,792 |
| Harga / Pendapatan (P/E TTM) | 15.95 |
| Harga / Pendapatan (P/E Ke hadapan) | 7.12 |
| Harga / Jualan (P/S) | 1.68 |
| Harga / Buku (P/B) | 2.86 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2026 |
| Margin Keuntungan | -3.12% |
| Margin Operasi (TTM) | 7.61% |
| EPS Cair (TTM) | -1.18 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 43.40% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -13.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 142.03% |
| Nisbah Semasa (MRQ) | 2.66 |
| Aliran Tunai Operasi (OCF TTM) | 80.74 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 39.80 M |
| Pulangan Atas Aset (ROA TTM) | 0.82% |
| Pulangan Atas Ekuiti (ROE TTM) | -4.57% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | ANI Pharmaceuticals, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -4.0 |
| Volatiliti Harga | 4.5 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 0.5 |
| Penilaian Relatif | -5.0 |
| Kesihatan Kewangan | NA |
| AI Insight | NA |
| Purata | 0.00 |
|
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 11.08% |
| % Dimiliki oleh Institusi | 100.39% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Ranger Investment Management, L.P. | 30 Jun 2026 | 343,150 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| COOK MEREDITH | - | 70.84 | -500 | -35,420 |
| LALWANI NIKHIL | - | 72.28 | -5,400 | -390,312 |
| Jumlah Keseluruhan Kuantiti Bersih | -5,900 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -425,732 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 71.56 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| LALWANI NIKHIL | Pegawai | 15 Oct 2026 | Jual automatik (-) | 5,400 | 72.28 | 390,312 |
| COOK MEREDITH | Pegawai | 13 Oct 2026 | Jual automatik (-) | 500 | 70.84 | 35,420 |
AI Analisis Teknikal
Buka tab Teknikal untuk menjana analisis terkini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |